3 results
Approved WMOPending
The primary objective is to characterize the change in the Pharmacodynamic (PD) biomarker, fecal calprotectin, during treatment with anrukinzumab.The secondary objectives include:* Characterization of the PK profile and total IL-13 of three multiple…
Approved WMOCompleted
In this study we aim to investigate the presence of CAN in diabetic patients scheduled for elective major abdominal and thoracic surgery and its relation with perioperative hemodynamic changes.
Approved WMOPending
The purpose of this study is to assess the safety and tolerability of intravenous 131I-TLX101 administered concomitantly and sequentially with standard of care in patients newly diagnosed with GBM, to determine the MTD and the R2PD.